Gain Therapeutics, Inc. filed an 8-K on July 16, 2025, announcing an underwriting agreement for an offering of 4,501,640 shares and 2,250,820 warrants, aiming to raise approximately $7.0 million, with expected net proceeds of about $6.3 million after expenses. The public offering price is set at $3.11 for every two shares and accompanying warrant.